From Barchart: 2024-10-24 08:04:52

Boston Scientific (NYSE:BSX) receives a price target increase from Citigroup despite a recent share price decline. The company reports a 7% drop in net income but exceeds revenue forecasts with a 19% surge, driven by cardiovascular product sales. Boston Scientific’s adjusted EPS of $0.63 beats projections, highlighting effective core operation management. Citigroup’s decision to raise the price target for Boston Scientific from $92 to $98 reflects optimism about the company’s growth potential. Despite a recent share price decline, Boston Scientific’s strong performance in cardiovascular product sales drove a 19% revenue increase to $4.21 billion. The company’s adjusted EPS of $0.63 exceeded expectations, showcasing effective core operation management.



Read more at Barchart:: Boston Scientific (NYSE:BSX) Maintains “Buy” Ratin…